{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:05:24Z","timestamp":1787015124193,"version":"build-2736575974"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2011,3,21]],"date-time":"2011-03-21T00:00:00Z","timestamp":1300665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Influenza Resp Viruses"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:p>\n                    <jats:italic>Please cite this paper as:<\/jats:italic>\n                    Yin\n                    <jats:italic>et\u00a0al.<\/jats:italic>\n                    (2011) Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta\u2010analysis. Influenza and Other Respiratory Viruses 5(5), 299\u2013305.\n                  <\/jats:p>\n                  <jats:p>\n                    The emergence of the 2009 H1N1 pandemic has highlighted the need to have immunogenicity and safety data on the new pandemic vaccines. There is already considerable heterogeneity in the types of vaccine available and of study performed around the world. A systematic review and meta\u2010analysis is needed to assess the immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccines. We searched Medline, EMBASE, the Cochrane Library and other online databases up to 1st October 2010 for studies in any language comparing different pandemic H1N1 vaccines, with or without placebo, in healthy populations aged at least 6\u2003months. The primary outcome was seroprotection according to haemagglutination inhibition (HI). Safety outcomes were adverse events. Meta\u2010analysis was performed for the primary outcome. We identified 18 articles, 1 only on safety and 17 on immunogenicity, although 1 was a duplicate. We included 16 articles in the meta\u2010analysis, covering 17\u2003921 subjects. Adequate seroprotection (\u226570%) was almost invariably achieved in all age groups, and even after one dose and at low antigen content (except in children under 3\u2003years receiving one dose of non\u2010adjuvanted vaccine). Non\u2010adjuvanted vaccine from international companies and adjuvanted vaccines containing oil in water emulsion (e.g. AS03, MF59), rather than aluminium, performed better. Two serious vaccination\u2010associated adverse events were reported, both of which resolved fully. No death or case of Guillain\u2013Barr\u00e9 syndrome was reported. The pandemic influenza (H1N1) 2009 vaccine, with or without adjuvant, appears generally to be seroprotective after just one dose and safe among healthy populations aged \u226536\u2003months; very young children (6\u201335\u2003months) may need to receive two doses of non\u2010adjuvanted vaccine or one dose of AS03\n                    <jats:sub>A\/B<\/jats:sub>\n                    \u2010adjuvanted product to achieve seroprotection.\n                  <\/jats:p>","DOI":"10.1111\/j.1750-2659.2011.00229.x","type":"journal-article","created":{"date-parts":[[2011,3,21]],"date-time":"2011-03-21T21:41:27Z","timestamp":1300743687000},"page":"299-305","source":"Crossref","is-referenced-by-count":43,"title":["Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"5","author":[{"given":"J. Kevin","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulam","family":"Khandaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harunor","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Heron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Ridda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Booy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,21]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"World Health Organization. Director General Statement following the meeting of the Emergency Committee 2009. Available athttp:\/\/www.who.int\/csr\/disease\/swineflu\/4th_meeting_ihr\/en\/index.html(Accessed 1 September 2010)."},{"key":"e_1_2_7_3_2","unstructured":"Note for guidance on harmonization of requirements for influenza vaccines. European Committee for Proprietary Medicinal Products 1997. Available athttp:\/\/www.emea.eu.int\/pdfs\/human\/bwp\/021496en.pdf(Accessed 20 October 2010)."},{"key":"e_1_2_7_4_2","unstructured":"Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines.US Food and Drug Administration 2007. Available athttp:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/ucm074786.htm(Accessed 20 October 2010)."},{"key":"e_1_2_7_5_2","unstructured":"European Medicines Agency.Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorisation Application 2008. Available athttp:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003869.pdf(Accessed 26 November 2010)."},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-18"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0022172400022610"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907650"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907413"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2649"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-9-80"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0909988"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.065"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.08.073"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62003-1"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.059"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1911"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.060"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62026-2"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.12.014"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/655830"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62039-0"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/655226"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908535"},{"key":"e_1_2_7_28_2","first-page":"1351","article-title":"Safety of influenza A (H1N1) 2009 monovalent vaccines \u2013 United States, October 1\u2013November 24, 2009","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.07.026"},{"key":"e_1_2_7_30_2","unstructured":"European Medicines Agency.Twenty\u2010second pandemic pharmacovigilance update. Available athttp:\/\/www.ema.europa.eu\/ema\/pages\/includes\/document\/open_document.jsp?webContentId=WC500095870(Accessed 17 January 2011)."},{"key":"e_1_2_7_31_2","first-page":"CD004876","article-title":"Vaccines for preventing influenza in the elderly","volume":"2","author":"Jefferson T","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_32_2","first-page":"CD004879","article-title":"Vaccines for preventing influenza in healthy children","volume":"2","author":"Jefferson T","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_33_2","unstructured":"Department of Health and Aging Australia.Panvax\u00ae H1N1 vaccine and ordering.2009. Available athttp:\/\/www.healthemergency.gov.au\/internet\/healthemergency\/publishing.nsf\/Content\/nvp\u2010qanda(Accessed 1 March 2010)."},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70153-7"},{"key":"e_1_2_7_35_2","unstructured":"Department of Health and Ageing Australia.Investigation into Febrile Convulsions in Young Children after Seasonal Influenza Vaccination Latest Findings and Recommendations 30 July 2010. Available athttp:\/\/www.health.gov.au\/internet\/immunise\/publishing...\/factsheet\u201030jul10.pdf(Accessed 9 December 2010)."},{"key":"e_1_2_7_36_2","first-page":"2157","article-title":"Evolutionary pattern of pandemic influenza (H1N1) 2009 virus in the late phases of the 2009 pandemic","volume":"3","author":"Valli MB","year":"2010","journal-title":"PLoS Curr"}],"container-title":["Influenza and Other Respiratory Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1750-2659.2011.00229.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1750-2659.2011.00229.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:23:16Z","timestamp":1697329396000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1750-2659.2011.00229.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,21]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1111\/j.1750-2659.2011.00229.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1750-2659.2011.00229.x","archive":["Portico"],"relation":{},"ISSN":["1750-2640","1750-2659"],"issn-type":[{"value":"1750-2640","type":"print"},{"value":"1750-2659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,21]]}}}